Life-Sciences-Asia.com
The Asian Life Sciences Web Portal

This is a free web portal for the life sciences in Asia... » read more

Boehringer: New Appointments to Board of Managing Directors (2024-08-30)
> Carinne Brouillon, member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit, to retire from Boehringer Ingelheim, effective October 1, 2024 > Shashank Deshpande, member of the Board of Managing Directors, appointed to le...
BioArctic: Leqembi (lecanemab) Approved in UK for Early AD (2024-08-22)
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, for the tr...
Vandria: CHF10.3m 2nd Closing Brings Series A to CHF28.3m (2024-08-21)
> Hevolution Foundation and Dolby Family Ventures join ND Capital as additional institutional investors bringing Series A funding to a total of $30.7M (CHF28.3M) > Vandria’s lead CNS compound VNA-318 is a mitophagy inducer about to enter clinical development ...
Fujifilm Diosynth Opens UK Microbial Manufacturing Facility (2024-08-20)
FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, today hosted a celebration for the opening of its microbial fermentation manufacturing ...
Adcendo Licenses Rights to ADC Candidate from Multitude Tx (2024-08-20)
Adcendo ApS (“Adcendo”) and Multitude Therapeutics Inc. (“Multitude”) jointly announced today that they have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with t...
BioNTech: FDA Lifts Partial Clinical Hold for BNT326/YL202 (2024-08-19)
On August 15, 2024, the U.S. Food and Drug Administration (“FDA”) lifted the partial clinical hold that was placed on MediLink Therapeutics’ (Suzhou) Co., Ltd. (“MediLink”) Phase I trial evaluating BNT326/YL202 (NCT05653752), which was announced on June 1...
Medigene and WuXi Biologics Enter Research Collaboration (2024-08-08)
> Partnership leverages Medigene’s leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics’ unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ > Collaboration is a t...
PL BioScience GmbH Closes €7.8m Series A Financing (2024-08-08)
> With the funding raised and the extensive experience of all partners, PL BioScience will scale up production capacities and strengthen the company’s position in thriving cell culture markets. > PL BioScience secures position as provider of growth-promoting c...
NEC Bio Therapeutics & AGC Biologics Announce Collaboration (2024-08-07)
NEC’s biotech arm and AGC’s life science division join forces to advance personalized treatment for patients suffering from cancer. Today, AGC Biologics and NEC Bio Therapeutics have announced a partnership to advance the production of NECVAX-NEO1, an oral...
Leon-Nanodrugs Closes Series D Led by LBBW Venture Capital (2024-08-06)
leon-nanodrugs GmbH (LEON), a pharmatech company specializing in the development of nanoencapsulation systems for genetic material and other active substances, announced today the closing of a Series D financing round. New lead investor LBBW Venture Capital closed ...

Life-Sciences-Asia.com is your doorway to the Asian life sciences!

[LSA] provides free, up-to-date and structured access to

– News
– Products
– Persons
– Organisations
– Financings
– Collaborations

in the Asian region.

Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSA] is 100% Made in Germany!

» Start here with the latest News!

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]